Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy
Overview
Authors
Affiliations
Background: Concentrations of tenofovir (TFV) in hair and tenofovir diphosphate (TFV-DP) in dried blood spots (DBSs) as measures of cumulative exposure have been primarily studied in younger, HIV-uninfected individuals taking preexposure HIV prophylaxis. Data on these measures among older HIV-infected individuals are limited.
Methods: We evaluated longitudinal TFV and TFV-DP concentrations in hair and DBS, respectively, from HIV-infected adults. Multivariable model variables included age group (18-35 and 60 years and older), creatinine clearance (CrCl), hematocrit (TFV-DP), and gray hair color (TFV).
Results: Baseline hair TFV and DBS TFV-DP were moderately correlated [r = 0.5 (0.2 to 0.7); P = 0.001] across both age groups [younger (N = 23) and older (N = 22)]. In adjusted models, CrCl was associated with increases of 15.9% (7.4% to 25.0%); P = 0.0006, and 5.7% (-0.2% to 11.9%); P = 0.057 for TFV in hair and TFV-DP in DBS, respectively, for every 20-mL/min CrCl decrease. Although older age (versus younger age) was univariately associated with increased TFV hair levels, older age was not significantly associated with higher concentrations in hair [-1.4% (-26.7% to 32.7%); P = 0.93] or DBS [4.0% (-14.1% to 25.9%); P = 0.68] after adjustment. Similarly, gray color was not significantly associated with higher TFV levels in hair [27.6% (-11.1% to 83.0%; P = 0.18)] in adjusted models. In both adjusted and unadjusted models of TFV-DP levels in DBS, a 1% hematocrit increase was associated with a 3.3% (0.2% to 6.5%) TFV-DP increase (P = 0.04).
Conclusions: Cumulative drug exposure measures (hair and DBS) were comparable in younger and older HIV-infected individuals on TFV-based therapy after adjustment for renal function.
Thompson B, Dilly-Penchala S, Amara A, Reynolds H, Khoo S, Else L Bioanalysis. 2023; 15(13):739-756.
PMID: 37293769 PMC: 10463213. DOI: 10.4155/bio-2023-0057.
Sharma A, Gandhi M, Sallabank G, Merrill L, Stephenson R Am J Mens Health. 2022; 16(4):15579883221115591.
PMID: 35950608 PMC: 9380227. DOI: 10.1177/15579883221115591.
Mwangi J, Gilliland Jr W, White N, Sykes C, Poliseno A, Knudtson K Antimicrob Agents Chemother. 2022; 66(4):e0217621.
PMID: 35266824 PMC: 9017293. DOI: 10.1128/aac.02176-21.
Kamkwalala A, Garg A, Roy U, Matthews A, Castillo-Mancilla J, Lake J AIDS Res Hum Retroviruses. 2021; 37(11):807-820.
PMID: 34405689 PMC: 8817696. DOI: 10.1089/AID.2021.0059.
Okochi H, Louie A, Phung N, Zhang K, Tallerico R, Kuncze K Drug Test Anal. 2021; 13(7):1354-1370.
PMID: 33742745 PMC: 9131373. DOI: 10.1002/dta.3033.